ReviewACS pharmacology & translational science2020
Strategic Moves of "Superbugs" Against Available Chemical Scaffolds: Signaling, Regulation, and Challenges.
Review in ACS pharmacology & translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Anthraquinones derived from soil actinomycetes combat multidrug-resistant Staphylococcus aureus.Communications biology · 2026Article
- Gromomycins: An Unprecedented Class of Triterpene Antibiotics Produced by a Novel Biosynthetic Pathway.Angewandte Chemie (International ed. in English) · 2025Article
- In Situ Nitric Oxide Generating Nano-Bioactive Glass-Based Coatings and Its Therapeutic Ion Release toward Attenuating Implant-Associated Fibrosis and Infection.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Dissemination and phenotypic characterization of ESBL-producingOpen veterinary journal · 2025Article
- Review
- Artificial intelligence-based prediction of pathogen emergence and evolution in the world of synthetic biology.Microbial biotechnology · 2024Review
- Pediatric Acute Myeloid Leukemia: Unraveling Complexities in Intensive Chemotherapy and the Emergence of Superbugs - A Case Study.Infection and drug resistance · 2024Article
- Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections.Pharmaceutics · 2023Review
- Multi-Function of a New Bioactive Secondary Metabolite Derived from Endophytic FungusJournal of microbiology and biotechnology · 2023Article
- Tryptone-stabilized silver nanoparticles' potential to mitigate planktonic and biofilm growth forms of Serratia marcescens.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2023Article
- Phages against killer superbugs: An enticing strategy against antibiotics-resistant pathogens.Frontiers in pharmacology · 2023Review
- Emergence of a Superplasmid Coharboring Hypervirulence and Multidrug Resistance Genes in Klebsiella pneumoniae Poses New Challenges to Public Health.Microbiology spectrum · 2022Article
- Interaction of Epigallocatechin Gallate and Quercetin with Spike Glycoprotein (S-Glycoprotein) of SARS-CoV-2: In Silico Study.Biomedicines · 2022Article
- Insights into Emergence of Antibiotic Resistance in Acid-Adapted EnterohaemorrhagicAntibiotics (Basel, Switzerland) · 2021Review
- β-Lactams against the Fortress of the Gram-PositiveChemical reviews · 2021Review
- Evaluation of Anti-Biofilm Capability of Cordycepin AgainstInfection and drug resistance · 2021Article
- Amphiphilic Aminoglycosides as Medicinal Agents.International journal of molecular sciences · 2020Review
- Targeting Antibiotic Resistance: From Diagnostics to Novel Antibiotics.ACS pharmacology & translational science · 2020Article
- Biomedically Relevant Applications of Bolaamphiphiles and Bolaamphiphile-Containing Materials.Frontiers in chemistry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Superbugs' resistivity against available natural products has become an alarming global threat, causing a rapid deterioration in public health and claiming tens of thousands of lives yearly. Although the rapid discovery of small molecules from plant and microbial origin with enhanced bioactivity has provided us with some hope, a rapid hike in the resistivity of superbugs has proven to be the biggest therapeutic hurdle of all times. Moreover, several distinct mechanisms endowed by these notorious superbugs make them immune to these antibiotics subsequently causing our antibiotic wardrobe to be obsolete. In this unfortunate situation, though the time frame for discovering novel "hit molecules" down the line remains largely unknown, our small hope and untiring efforts injected in hunting novel chemical scaffolds with unique molecular targets using high-throughput technologies may safeguard us against these life-threatening challenges to some extent. Amid this crisis, the current comprehensive review highlights the present status of knowledge, our search for bacteria Achilles' heel, distinct molecular signaling that an opportunistic pathogen bestows to trespass the toxicity of antibiotics, and facile strategies and appealing therapeutic targets of novel drugs. Herein, we also discuss multidimensional strategies to combat antimicrobial resistance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.